Welcome to our dedicated page for Paysign news (Ticker: PAYS), a resource for investors and traders seeking the latest updates and insights on Paysign stock.
Paysign, Inc. reports developments in patient affordability programs, donor compensation solutions, engagement and management platforms, and integrated payment processing for the life sciences industries. The company operates at the intersection of fintech and healthcare, serving plasma, pharmaceutical and life sciences customers with payment and program-management technologies.
Recurring updates cover earnings results, patient affordability growth, pharmaceutical copay program performance, claims-processing activity, plasma donor compensation revenue, and SaaS engagement technologies for donor and program management. Company announcements also discuss Dynamic Business Rules for mitigating copay accumulators and maximizers, physical, virtual, mobile and bank-based payment capabilities, reporting and analytics, and investor conference participation.
Paysign (NASDAQ:PAYS) reported strong first quarter 2026 results, with revenue of $28.04 million, up 50.8% year over year. Pharma revenue rose 81.9% to $15.68 million and plasma revenue grew 24.9% to $11.75 million.
Operating margin expanded to 23.8% from 13.4%, while net income increased 110.3% to $5.44 million, or $0.09 per diluted share. Adjusted EBITDA rose 113.4% to $10.59 million. Paysign ended the quarter with $20.55 million in unrestricted cash and no bank debt. Full-year 2026 guidance calls for revenue of $106.5–$110.5 million, 30–35% growth, and net income of $13–$16 million.
Paysign (NASDAQ: PAYS) will host its first quarter 2026 earnings call at 5:00 p.m. ET on Tuesday, May 12, 2026. The company provided dial-in numbers, a webcast link, and replay details; the replay is available until August 12, 2026. Financial professionals wishing to ask questions must register by 5:00 p.m. ET on Friday, May 8, 2026 via email.
Paysign (NASDAQ: PAYS) reported strong 2025 results: $82.02M revenue (+40.5%), net income of $7.55M and Adjusted EBITDA $19.94M (+107.3%). Pharma revenue grew 167.8% and patient affordability programs rose to 131. Company exited 2025 with $21.07M unrestricted cash, $143.92M restricted cash and zero debt. 2026 guidance targets $106.5M–$110.5M revenue and $30M–$33M adjusted EBITDA.
Paysign (NASDAQ: PAYS) will host its fourth quarter and full year 2025 earnings call on Tuesday, March 24, 2026 at 5:00 p.m. ET. Investors can join via U.S. and international dial-ins or a live webcast. Replay is available through June 24, 2026.
Financial professionals who wish to ask questions must register by emailing ir@paysign.com by 5:00 p.m. ET on Friday, March 20, 2026.
Paysign (NASDAQ: PAYS) will present at the Oppenheimer 11th Annual Emerging Growth Conference, held February 3-4, 2026, in a virtual format. The conference features one-on-one and small-group meetings with emerging companies across technology, industrial growth and consumer sectors. Paysign’s CFO Jeff Baker will host one-on-one investor meetings on Tuesday, February 3, 2026. Investors interested in attending are instructed to contact their Oppenheimer representative to register.
Paysign (NASDAQ: PAYS) reported 2025 patient affordability results showing material growth and measurable savings. The company exited 2025 with 131 active programs (added 55 in 2025), a >70% increase versus 2024, and supported >840,000 unique patients. Paysign said its Dynamic Business Rules feature identifies impacted claims on first fill with 97% accuracy and helped mitigate copay maximizers, saving pharmaceutical program sponsors more than $325 million in 2025 (an increase of >200% from 2024). Paysign also reported assisting clients in delivering more than $950 million toward prescription fulfillment expenses in 2025.
The release frames these metrics as evidence of expanded healthcare presence and enhanced value delivery to patients and pharmaceutical sponsors.
Paysign (NASDAQ: PAYS) will present at the 17th Annual Southwest IDEAS Investor Conference in Dallas, Texas on November 19–20, 2025. The invitation-only conference connects public companies with institutional investors via one-on-one and group meetings.
Paysign's CFO Jeff Baker will present on Thursday, November 20, 2025 and is available for one-on-one meetings during the event.
Paysign (NASDAQ: PAYS) reported record Q3 2025 results with $21.60M revenue, up 41.6% year-over-year, and net income of $2.22M (diluted EPS $0.04), up 54.2%. Adjusted EBITDA was $5.04M (23.3% margin), up 78.1%. Pharma patient affordability revenue grew 141.9% to $7.92M with 105 active programs at quarter end (118 at Oct 31). Plasma revenue rose 12.4% to $12.86M with 595 centers. Ended Q3 with $7.53M unrestricted cash and zero bank debt; unrestricted cash was reduced by timing on $9.36M passthrough claim items. Updated 2025 guidance: revenue $80.5M–$81.5M, net income $7.0M–$8.0M, Adjusted EBITDA $19M–$20M.
Paysign (NASDAQ: PAYS) will host its third quarter 2025 earnings call on Wednesday, November 12, 2025 at 5:00 p.m. ET. The company will discuss third-quarter results and answer questions from registered financial professionals.
Participant details: U.S. dial-in 877.407.2988; International +1.201.389.0923; Webcast available live. Replay: dial 877.660.6853 or +1.201.612.7415, Conference ID 13756404; replay available through May 12, 2026. To ask questions live, financial professionals must register by emailing ir@paysign.com by 5:00 p.m. ET on Friday, November 7, 2025.
Paysign (NASDAQ: PAYS), a provider of patient affordability programs and donor compensation solutions, has appointed Jose Garcia as Executive Vice President of Life Science Solutions. Garcia, with over 20 years of executive experience, will lead the market strategy for the company's engagement and management solutions in life sciences.
Prior to joining Paysign, Garcia served as Vice President of Client Relationships at QualTex Laboratories, where he strengthened partnerships in blood and plasma collection industries. He previously held VP of Sales positions at BioBridge Global companies, QualTex and GenCure, expanding their life sciences presence.